Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
The USFDA has issued 15 observations pursuant to the completion of audit. JHSGP will submit an action plan on the observations
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
Prior to taking charge at the Union Health Ministry, Jadhav planted a sapling at his residence
Dr. Reddy's Laboratories gets Form 483 from USFDA with 4 observations for API facility
This strategic decision will unlock significant value for our scientific and industrial products business
PICCOLO trial met its primary endpoint of objective response rate (ORR)
Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response
Subscribe To Our Newsletter & Stay Updated
